This innovative drug works by targeting pain-signaling pathways in the peripheral nervous system to reduce pain before signals reach the brain.
Dr. Christopher Gharibo emphasizes that Journavx does not produce a high, cravings, or withdrawal symptoms, which are significant concerns with traditional opioids.
A new non-opioid pain medication named Journavx has received FDA approval, marking the first new pain treatment in over 20 years and is described as non-addictive.
Journavx is specifically intended for the treatment of moderate to severe acute pain in adults, particularly for short-term relief following surgeries or injuries.
However, the drug comes with a list price of $15.50 per pill, which is significantly higher than many generic opioids that can cost $1 or less.
Details regarding the pricing strategy for Journavx are currently unclear, raising questions about affordability for patients.
Dr. Gharibo highlights that obtaining insurance coverage for Journavx may be challenging, as patients might need to navigate a prior authorization process.
A mother who lost her son to opioid addiction expresses cautious optimism about Journavx, hoping it will serve as a safe alternative to opioids.
Traditional pain management often relies on opioids, which have led to addiction and contributed to tens of thousands of deaths annually in the U.S.
Vertex began developing Journavx in response to rising opioid overdose rates driven by excessive prescribing of opioid medications.
In clinical studies involving over 870 patients, Journavx demonstrated effectiveness in pain reduction after surgery compared to a placebo, though it was less effective than the combination of opioids and acetaminophen.
Despite the higher cost, market response has been positive, with analysts predicting potential annual sales exceeding $1 billion.
